A recent study from Howard Hughes Medical Institute, Center for Stem Cell Biology, NYU School of Medicine, 550 First Avenue, New York, USA has reported the role of Notch-regulated lncRNA LUNARI in Acute Leukemia. This study was published in the July 31 2014 Cell (I.F: >35; The number 1 journal in basic biology) by Prof Iannis Aifantis, Thomas Trimarchi and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic and Therapeutic insights into the treatment of Human Leukemia: Tumor suppressor ING1b inhibits acute leukemia via down regulation of Notch-regulated pro-oncogenic lncRNA LUNAR1. This study suggests that ING1b, by decreasing the expression of Notch-1, lncRNA LUNAR1 and IGF1R mRNA, it may inhibit acute leukemia. Together, this study suggests that pharmacological formulations encompassing “ING1b activators” may be used to treat patients (with no mutation or deletion in the ING1b gene) suffering from leukemia.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Mechanistic and Therapeutic insights into the treatment of Human Leukemia: Tumor suppressor ARF inhibits acute leukemia via down regulation of Notch-regulated pro-oncogenic lncRNA LUNAR1., 17/August/2014, 06.21 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
